From 'gills to pills': Urotensin-II as a regulator of mammalian cardiorenal function

Trends in Pharmacological Sciences

Volumn 25, Issue 2, 2004, Pages 76-85

  Douglas, Stephen A ^a   Dhanak, Dashyant ^a   Johns, Douglas G ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; G PROTEIN COUPLED RECEPTOR; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; RECEPTOR BLOCKING AGENT; SOMATOSTATIN; UROTENSIN II;

CARDIOVASCULAR EFFECT; CELL GROWTH; DRUG ACTIVITY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ENDOCRINE FUNCTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HORMONAL REGULATION; HUMAN; HYPERTENSION; IC 50; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAMMAL; NUCLEAR MAGNETIC RESONANCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BLOCKING; REVIEW; STRUCTURE ACTIVITY RELATION; VASOCONSTRICTION; VASODILATATION;

EID: 0842266248     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2003.12.005     Document Type: Review

References (97)

1. Conlon J.M., et al. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J. Exp. Zool. 275:1996;226-238.
2. Itoh H., et al. Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am. J. Physiol. 252:1987;R361-R366.
3. Ames R.S., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 401:1999;282-286.
4. Douglas S.A., Ohlstein E.H. Urotensin receptors. Girdlestone D. The IUPHAR Compendium of Receptor Characterization and Classification. 2000;365-372 IUPHAR Media, London.
5. Elshourbagy N., et al. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br. J. Pharmacol. 136:2002;9-22.
6. Nothacker H.-P., et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat. Cell Biol. 1:1999;383-385.
7. Matsushita M., et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J. Hypertens. 19:2001;2185-2190.
8. Shenouda A., et al. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J. Histochem. Cytochem. 50:2002;885-889.
9. Maguire J.J., et al. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol. 131:2000;441-446.
10. MacLean M.R., et al. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br. J. Pharmacol. 130:2000;201-204.
11. Paysant J., et al. Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II. Fundam. Clin. Pharmacol. 15:2001;227-231.
12. Russell F.D., et al. Cardiostimulant effects of urotensin-II in human heart in vitro. Br. J. Pharmacol. 132:2001;5-9.
13. Camarda V., et al. Effects of human urotensin II in isolated vessels of various species: comparison with other vasoactive agents. Naunyn Schmiedebergs Arch. Pharmacol. 365:2002;141-149.
14. Behm D.J., et al. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br. J. Pharmacol. 139:2003;464-472.
15. Opgaard O.S., et al. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur. J. Pharmacol. 406:2000;265-271.
16. Douglas S.A., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br. J. Pharmacol. 131:2000;1262-1274.
17. Douglas S.A. Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr. Opin. Pharmacol. 3:2003;159-167.
18. Gibson A. Complex effects of Gillichthys urotensin II on rat aortic strips. Br. J. Pharmacol. 91:1987;205-212.
19. Bottrill F.E., et al. Human urotensin II is an endothelium-dependent vasodilator in rat small arteries. Br. J. Pharmacol. 130:2000;1865-1870.
20. Katano Y., et al. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors on rat coronary arteries. Eur. J. Pharmacol. 402:2000;R5-R7.
21. Gray G.A., et al. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci. 69:2001;175-180.
22. Stirrat A., et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am. J. Physiol. Heart Circ. Physiol. 280:2001;H925-H928.
23. Hillier C., et al. Effects of urotensin II in human arteries and veins of varying caliber. Circulation. 103:2001;1378-1381.
24. Gardiner S.M., et al. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br. J. Pharmacol. 132:2001;1625-1629.
25. Gibson A., et al. Cardiovascular effects of urotensin II in anesthetized and pithed rats. Gen. Comp. Endocrinol. 64:1986;435-439.
26. Hasegawa K., et al. Vasodepressor effects of urotensin II in rats. Neuroendocrinol. Lett. 14:1992;357-363.
27. Abdelrahman A.M., Pang C.C.Y. Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci. 71:2002;819-825.
28. Hassan G.S., et al. Effect of human urotensin-II infusion on hemodynamics and cardiac function. Can. J. Physiol. Pharmacol. 81:2003;125-128.
29. Bennett T., et al. Regional haemodynamic responses to infusion of human urotensin II (hUII) in conscious Sprague-Dawley rats. Br. J. Pharmacol. 135:2002;200.
30. Vergura R., et al. Urotensin II stimulates plasma extravasation in mice via UT receptor activation. Br. J. Pharmacol. 138:2003;160.
31. Leslie, S.J. et al. (2000) Human urotensin II causes vasoconstriction in the human skin microcirculation. Circulation 102, II-113.
32. Böhm F., Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br. J. Pharmacol. 135:2002;25-27.
33. Wilkinson I.B., et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc. Res. 53:2002;341-347.
34. Affolter J.T., et al. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br. J. Clin. Pharmacol. 54:2002;617-621.
35. i transient. Circulation 106, II-26.
36. Douglas S.A., et al. Congestive heart failure and expression of myocardial urotensin II. Lancet. 359:2002;1990-1997.
37. Richards A.M., et al. Plasma urotensin II in heart failure. Lancet. 360:2002;545-546.
38. Ng L.L., et al. Plasma urotensin in human systolic heart failure. Circulation. 106:2002;2877-2880.
39. Dschietzig T., et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul. Pept. 110:2002;33-38.
40. Coulouarn Y., et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15803-15808.
41. Coulouarn Y., et al. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett. 457:1999;28-32.
42. Sawada M., Ichinose M. Potentiation of GABA(A) receptor-mediated Cl-current by urotensin peptides in identified Aplysia neurons. J. Neurosci. Res. 56:1999;547-552.
43. Brailoiu E., et al. The vasoactive peptide urotensin II stimulates spontaneous release from frog motor nerve terminals. Br. J. Pharmacol. 138:2003;1580-1588.
44. Filipeanu C.M., et al. Urotensin II regulates intracellular calcium in dissociated rat spinal cord neurons. J. Neurochem. 83:2002;879-884.
45. Lin Y., et al. Central cardiovascular action of urotensin II in conscious rats. J. Hypertens. 21:2003;159-165.
46. Lu Y., et al. Cardiovascular effects of urotensin II in different brain areas. Peptides. 23:2002;1631-1635.
47. Bond H., et al. Plasma concentrations of arginine vasotocin and urotensin II are reduced following transfer of the euryhaline flounder (Platichthys flesus) from seawater to fresh water. Gen. Comp. Endocrinol. 125:2002;113-120.
48. Bern H.A., et al. Neurohormones from fish tails: the caudal neurosecretory system.I: 'urophysiology' and the caudal neurosecretory system of fishes. Recent Prog. Horm. Res. 41:1985;533-552.
49. Winter M.J., et al. A homologous radioimmunoassay for the measurement of urotensin II in the euryhaline flounder, Platichthys flesus. Gen. Comp. Endocrinol. 114:1999;249-256.
50. Loretz C.A. Ion transport in goby intestine: cellular mechanism of urotensin II stimulation. Am. J. Physiol. 249:1985;G284-G293.
51. Matsushita M., et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. Endocrinology. 144:2003;1825-1831.
52. Totsune K., et al. Role of urotensin II in patients on dialysis. Lancet. 358:2001;810-811.
53. Totsune K., et al. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin. Sci. 104:2003;1-5.
54. Zhang A.Y., et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am. J. Physiol. Renal Physiol. 285:2003;F792-F798.
55. Watson A.M., et al. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension. 42:2003;373-379.
56. Gartlon J., et al. Central effects of urotensin-II following ICV administration in rats. Psychopharmacology (Berl.). 155:2001;426-433.
57. Silvestre R.A., et al. Inhibition of insulin release by urotensin II - a study on the perfused rat pancreas. Horm. Metab. Res. 33:2001;379-381.
58. Wenyi Z., et al. Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia. 46:2003;972-976.
59. Cohn J.N. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation. 91:1995;2504-2507.
60. Katz A.M. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann. Intern. Med. 121:1994;363-371.
61. Zou Y., et al. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett. 508:2001;57-60.
62. Tamura K., et al. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci. 72:2003;1049-1060.
63. Sauzeau V., et al. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by rhoA and rho-kinase. Circ. Res. 88:2001;1102-1104.
64. Watanabe T., et al. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J. Hypertens. 19:2001;2191-2196.
65. Watanabe T., et al. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation. 104:2001;16-18.
66. Watanabe T., et al. Lysophosphatidylcholine potentiates the mitogenic effect of various vasoactive compounds on rabbit aortic smooth muscle cells. Jpn. Heart J. 43:2002;409-416.
67. Johns, D.G. et al. (2002) Urotensin-II-dependent cardiomyocyte hypertrophy: role in congestive heart failure. Circulation 106, II-291.
68. Tzanidis A., et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ. Res. 93:2003;246-253.
69. Krum H., et al. Increased expression of urotensin II and its receptor in an experimental model of left ventricular myocardial infarction in the rat: implications for cardiac remodelling. Eur. Heart J. 22:2001;141.
70. Heller J., et al. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J. Hepatol. 37:2002;767-772.
71. Itoh H., et al. Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur. J. Pharmacol. 149:1988;61-66.
72. Coy D.H., et al. Structural requirements at the N-terminus of urotensin II octapeptides. Peptides. 23:2002;2259-2264.
73. Flohr S., et al. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J. Med. Chem. 45:2002;1799-1805.
74. Grieco P., et al. Design, synthesis, conformational analysis and biological studies of urotensin-II lactam analogues. Bioorg. Med. Chem. 10:2002;3731-3739.
75. Kinney W.A., et al. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew. Chem. Int. Ed. Engl. 41:2002;2940-2944.
76. Grieco P., et al. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J. Med. Chem. 45:2002;4391-4394.
77. Croston G.E., et al. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl) isochroman-1-one (AC-7954). J. Med. Chem. 45:2002;4950-4953.
78. Behm D.J., et al. Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br. J. Pharmacol. 137:2002;449-458.
79. Rossowski W.J., et al. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur. J. Pharmacol. 438:2002;159-170.
80. Herold C.L., et al. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. Br. J. Pharmacol. 139:2003;203-207.
81. Dhanak & Knight (2001) Urotensin-II receptor antagonists. WO0145694.
82. Dhanak et al. (2001) Urotensin-II receptor antagonists. WO0145711.
83. Tarui et al. (2001) Vasoactive agents. WO0166143.
84. Tarui, N. et al. (2002) Biphenyl compound. WO0200606.
85. Tarui N., et al. GPR14 antagonist. 2002;WO0202530.
86. Aissaoui et al. (2002) Preparation of 1,2,3,4-tetrahydroisoquinolinyl ureas and related derivatives as urotensin II receptor antagonists. WO0276979.
87. Dhanak et al. (2002) Preparation of N-(2-quinolinyl)propane-1,3-diamines as urotensin-II receptor antagonists. WO0258702.
88. Protopopov A., et al. Assignment of the GPR14 gene coding for the G-protein-coupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridization. Cytogenet. Cell Genet. 88:2000;312-313.
89. Itoh H., et al. Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur. J. Pharmacol. 149:1988;61-66.
90. Liu Q., et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem. Biophys. Res. Commun. 266:1999;174-178.
91. Boucard A.A., et al. Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain. Biochem. J. 370:2003;829-838.
92. Mori M., et al. Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem. Biophys. Res. Commun. 265:1999;123-129.
93. Labarrere P., et al. Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. J. Enzyme Inhib. Med. Chem. 18:2003;77-88.
94. Brkovic A., et al. Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay. J. Pharmacol. Exp. Ther. 306:2003;1200-1209.
95. Maguire J.J., Davenport A.P. Is urotensin-II the new endothelin? Br. J. Pharmacol. 137:2002;579-588.
96. Hay D.W., et al. Human urotensin-II is a potent spasmogen of primate airway smooth muscle. Br. J. Pharmacol. 131:2000;10-12.
97. Marchese A., et al. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics. 29:1995;335-344.